ICG122 / iCell Gene Therap - LARVOL DELTA

CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Huda Salman | Trial completion date: Dec 2037 ➔ Dec 2040

Trial completion date • Acute Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD4

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Huda Salman | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD4

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Huda Salman | Initiation date: Oct 2023 ➔ Jan 2024

CAR T-Cell Therapy • Trial initiation date • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD4

CD4CAR T Cell Therapy as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Huda Salman

CAR T-Cell Therapy • New P1 trial • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD14 • CD4 • FOXP3 • PTPRC

CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Huda Salman | Active, not recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Cutaneous T-cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD4 • IL10 • IL2 • IL6 • TNFA

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells. (PubMed, Front Immunol) - "Additionally, infusion led to the depletion of CD4+ Treg cells and expansion of CD3+CD8+ T cells and NK cells. These results suggest that CD4-IL15/IL15sushi CAR T cells may be a safe and effective treatment for patients with relapsed or refractory T-cell lymphomas, where new treatment options are needed."

CAR T-Cell Therapy • Journal • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD4 • IL15

CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Huda Salman | Trial primary completion date: Dec 2022 ➔ Dec 2025

Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD4 • IL10 • IL2 • IL6 • TNFA

CD4CAR for CD4+ Leukemia and Lymphoma (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Huda Salman; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD4 • IFNG • IL10 • IL2 • IL6 • MRI • TNFA

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: iCell Gene Therapeutics; Initiation date: Nov 2019 ➔ Jul 2019

Trial initiation date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma (ASH 2019) - "An alemtuzumab safety switch has also been established to ensure the elimination of CAR T cells following tumor eradication...Patient received a total dose of 3x10^6 /kg single dose CAR T cells, following which fluconazole and valacyclovir were administrated for infection prophylaxis...Conclusion Our first-in-human clinical trial demonstrates promising efficacy of CD4 CAR T cell therapy in treating patients with refractory Sezary syndrome. cCAR is able to eradicate leukemia blasts, exerting a profound tumor killing effect that is superior to traditional chemotherapies."

Clinical • P1 data • CD8

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: iCell Gene Therapeutics

New P1 trial